Regeneron Lifts Stake In Biotech Partner ISA Pharma
Equity Injection Part Of €26m Funding To Advance ISA’s Pipeline
Armed with €26m in fresh funds from investors that include partner Regeneron, ISA Pharma can now advance promising preclinical assets generated from its proprietary platform, containing a mix of synthetic antigenic peptides, its CEO tells Scrip.
You may also be interested in...
Private Company Edition: With $8.9bn raised in the second quarter, venture capital investment in biopharma companies reached its second highest quarterly total to date – behind only Q1 of this year. Also, Nimbus Therapeutics raised $105m and European drug developers get in on the VC action.
The Sanofi/Regeneron PD-1 inhibitor Libtayo has become the first immunotherapy to demonstrate an improved overall survival in patients with cervical cancer in a Phase III trial.
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.